Therapeutics News and Research

RSS

Next Generation Advanced Image Processing for Toshiba Infinix-i product line

Improving the ability to provide premium patient care during interventional procedures, Toshiba America Medical Systems, Inc. is expanding the availability of Next Generation Advanced Image Processing (AIP) to more systems in the Toshiba InfinixTM-i product line.

16 Sep 2009

New therapies boost obesity drug market

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the uptake of novel therapies will drive the obesity drug market to increase more than six-fold, from $512 million in 2008 to more than $3.2 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

16 Sep 2009

RXi Pharmaceuticals to present in vivo data of rxRNA compounds

RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that it will be presenting new in vivo data on its self-delivering rxRNA compounds at a number of upcoming scientific conferences, detailed below.

16 Sep 2009

Toll-like receptors that activate immune cells being developed as alternative cure to cancer

A Toll-like receptor (TLR) agonist, called imiquimod, which activates dendritic cells, is in clinical use as a topical application for basal cell carcinoma. In addition, a number of TLR agonists have been evaluated in clinical trials as an adjuvant for cancer vaccines.

16 Sep 2009

EVEREST clinical trial results to be presented at the upcoming TCT Conference

The upcoming Transcatheter Cardiovascular Therapeutics (TCT) Conference, to take place in San Francisco from September 21-25, will serve as a backdrop for the presentation of EVEREST registry clinical results of the MitraClip(R) therapy for patients with mitral regurgitation (MR).

16 Sep 2009

LEAD Therapeutics' LT-29 antibiotic effective against most common antibiotic resistant bacteria

LEAD Therapeutics, a privately held drug discovery company, announced the discovery of a novel antibiotic with potent activity against many of the most common antibiotic resistant bacteria.

16 Sep 2009

GENova allies with academic institutions specializing in stem cell research

GENova Biotherapeutics Inc. ("GENova") today announced that it is forming strategic alliances with academic research institutions specializing in ground-breaking stem cell research.

16 Sep 2009

Phase III EXTEND trial results of pixantrone announced

Cell Therapeutics, Inc. (CTI) today released updated 18-month follow-up clinical data for its phase III EXTEND (PIX 301) trial of pixantrone (BBR2778) for patients with advanced, relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL). Responses were evaluated by an Independent Assessment Panel that was blinded to patient assignment.

16 Sep 2009

BCLI collaborates with HBI to complete pre-clinical safety experiments

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, announced today that it has entered into a strategic agreement with Harlan Biotech Israel Ltd (HBI), a leading Good Laboratory Practice contractor, in order to complete pre-clinical safety experiments for the company’s innovative therapy for ALS (Amyotrophic Lateral Sclerosis, also known as Lou Gehrig’s disease).

15 Sep 2009

Alvine Pharmaceuticals raises funds for Phase 2a clinical trial of its lead compound ALV003

Alvine Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on developing and commercializing therapeutics for autoimmune/gastrointestinal diseases, today announced the closing of a $21.5 million extension of its Series A financing.

15 Sep 2009

Hyperion enrolls first patient in HPN-100 investigational compound clinical trial

Hyperion Therapeutics today announced that the first patient has been enrolled in a clinical trial of investigational compound HPN-100 (glycerol phenylbutyrate) in children ages 6-17 with urea cycle disorders (UCD). The study will evaluate the safety, tolerability, and ammonia control of glycerol phenylbutyrate compared to BUPHENYL® (sodium phenylbutyrate).

15 Sep 2009

Tryton Side Branch Stent used in 250 procedures to treat atherosclerotic lesions

Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, announced today that the company’s Tryton Side Branch Stent has been used in 250 procedures to treat atherosclerotic lesions at a bifurcation in patients with heart disease.

15 Sep 2009

Halozyme Therapeutics to present its product development pipeline

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced its participation in the UBS Global Life Sciences Conference to be held on September 21-23, 2009 in New York City.

15 Sep 2009

Alnylam and Medtronic announce pre-clinical research findings from their Huntington’s disease program

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Medtronic, Inc. (NYSE: MDT), the world’s leading developer of medical devices, announced today the presentation of new pre-clinical research findings from their Huntington’s disease program at the 2009 World Congress on Huntington’s Disease held September 12-15, 2009 in Vancouver, British Columbia.

15 Sep 2009

HUYA Bioscience signs first-look agreement with Chinese Academy of Sciences' GIBH

HUYA Bioscience International, the leader in global pharmaceutical co-development with China, today announced a strategic partnership agreement with Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (GIBH). HUYA has established a series of strategic partnerships with Chinese science institutes that affords it the opportunity to expand its portfolio of novel biopharmaceutical products.

15 Sep 2009

Cardium's Gene Activated Matrix technology demonstrates benefits in periodontal tissue regeneration

Cardium Therapeutics (NYSE Amex: CXM) today reported on preclinical findings published in the scientific journal, Gene Therapy, demonstrating that Cardium's Gene Activated Matrix(TM) or GAM(TM) technology accelerates periodontal tissue regeneration of oral implant-supporting wounds.

15 Sep 2009

Clinical trial data of Genous Bio-engineered R stent to be presented

Data from multiple clinical trials of the world's first pro-healing stent, OrbusNeich's Genous Bio-engineered R stent, and preclinical data from Combo Bio-engineered Sirolimus Eluting Stent will be presented next week at the Transcatheter Cardiovascular Therapeutics symposium, TCT 2009, in San Francisco.

15 Sep 2009

Stem cell therapy holds great promise for regenerative medicine

The recipients of The 2009 Lasker Awards, announced today, represent the dramatic advances achieved in biotechnology research that have led to a revolutionary cancer treatment and the tremendous promise of stem cell therapy for regenerative medicine. Such advances portend a potential $700 million global market for new therapies within less than five years, according to Genetic Engineering & Biotechnology News (GEN, www.genengnews.com).

15 Sep 2009

Phase II clinical study results of Kamada's inhaled-AAT for cystic fibrosis presented at the ERS Congress

Kamada, a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced that data on its next-generation alpha-1 antitrypsin (Inhaled-AAT) in cystic fibrosis patients was presented today, at the Annual Congress of the European Respiratory Society (ERS) 2009, Vienna. As previously reported, the study showed that inhaled-AAT was safe and biologically effective.

15 Sep 2009

Cell Therapeutics submits Pediatric Investigation Plan to EMEA for pixantrone

Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has submitted a Pediatric Investigation Plan (PIP) to the European Medicines Agency (EMEA) as part of the required filing process for approval of pixantrone for treating relapsed or refractory, aggressive non-Hodgkin's Lymphoma (NHL) in Europe. The PIP outlines how the company proposes to study the drug in children in order to benefit child health.

15 Sep 2009

Therapeutics News and Research

Next Generation Advanced Image Processing for Toshiba Infinix-i product line

New therapies boost obesity drug market

RXi Pharmaceuticals to present in vivo data of rxRNA compounds

Toll-like receptors that activate immune cells being developed as alternative cure to cancer

EVEREST clinical trial results to be presented at the upcoming TCT Conference

LEAD Therapeutics' LT-29 antibiotic effective against most common antibiotic resistant bacteria

GENova allies with academic institutions specializing in stem cell research

Phase III EXTEND trial results of pixantrone announced

BCLI collaborates with HBI to complete pre-clinical safety experiments

Alvine Pharmaceuticals raises funds for Phase 2a clinical trial of its lead compound ALV003

Hyperion enrolls first patient in HPN-100 investigational compound clinical trial

Tryton Side Branch Stent used in 250 procedures to treat atherosclerotic lesions

Halozyme Therapeutics to present its product development pipeline

Alnylam and Medtronic announce pre-clinical research findings from their Huntington’s disease program

HUYA Bioscience signs first-look agreement with Chinese Academy of Sciences' GIBH

Cardium's Gene Activated Matrix technology demonstrates benefits in periodontal tissue regeneration

Clinical trial data of Genous Bio-engineered R stent to be presented

Stem cell therapy holds great promise for regenerative medicine

Phase II clinical study results of Kamada's inhaled-AAT for cystic fibrosis presented at the ERS Congress

Cell Therapeutics submits Pediatric Investigation Plan to EMEA for pixantrone

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News